PDCD1 and neoplasm: Increased CD154 expression and cytokine release can effectively activate CD4+ tumor-infiltrating lymphocytes (TILs) during anti-PD-1 therapy, which promotes dendritic cell development and enhances CD8+ TIL multiplication.